European economic fears don’t warrant more price cuts, says GSK’s Witty
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline CEO Andrew Witty believes that economic concerns in Europe are perhaps being overstated amid the financial turmoil there, though he warned that the pharmaceutical industry may not be able to absorb many more price cuts.